NOTV

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2004, for Bioanalytical Systems, Inc. (Note: The request metadata lists "Inotiv, Inc.", but the filing text identifies the registrant as Bioanalytical Systems, Inc., or BASi). The company provides laboratory services and manufactures scientific instruments for pharmaceutical development. The reporting period includes the three and six months ended March 31, 2004, compared to the same periods in 2003.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 24% for the quarter and 25% for the six-month period compared to the prior year, driven primarily by the Services segment following two acquisitions completed in fiscal 2003.
• Margin Compression: Gross profit margins declined from 32.5% to 25.5% (quarterly) due to operating inefficiencies during the integration of acquired businesses and underutilization of new capacity. Cost of service revenue rose to 93% of service revenue.
• Operating Expenses: General and administrative expenses increased 49% for the quarter and 59% for the six months, attributed to acquisition-related costs and financial consulting fees following the CFO resignation. Selling and R&D expenses decreased due to cost-control measures.
• Profitability: The company reported a net loss of $0.50 million for the quarter, compared to a loss of $0.17 million in the prior year quarter. For the six months, the loss was $0.63 million versus a net income of $0.11 million in the prior year.
• Interest Expense: Interest expense increased 50% for the quarter and 67% for the six months due to subordinated debt from acquisitions and facility expansion loans.

Outlook, Risks, and Management Commentary

• Capacity Utilization: Management notes that profitability is heavily dependent on capacity utilization. Recent expansions in West Lafayette, Evansville, Baltimore, and McMinville have increased fixed costs, which are currently being spread over less-than-capacity revenues.
• Liquidity and Covenants: The company was in violation of a financial covenant regarding interest-bearing indebtedness to EBITDA for the first two quarters of fiscal 2004. Banks granted waivers in January and May 2004, conditioned on granting a secured mortgage on the Baltimore facility. The company is actively managing cash flow and has ceased new capital expenditures for expansion.
• Debt Obligations: Total contractual debt and lease obligations are approximately $16.9 million. The revolving line of credit expires in September 2006, with approximately $2.1 million available as of March 31, 2004.
• Strategic Actions: The company is reorganizing business development, implementing IT improvements, and attempting to sell the Baltimore physical facility to improve liquidity. A new CFO was hired in March 2004.
• Market Risks: The business is sensitive to pharmaceutical industry consolidation and drug development cycles. Foreign currency fluctuations (specifically the British pound) impacted UK-based revenues positively in the quarter.

Investor Verification Checklist

• Covenant Compliance: Verify the status of the financial covenant waivers and the secured mortgage on the Baltimore facility granted to banks.
• Capacity Utilization Rates: Monitor future reports for improvements in the utilization of the new facilities in West Lafayette and Baltimore to assess margin recovery.
• Debt Conversion: Confirm the conversion of the $2.25 million construction line of credit into a term note as scheduled for May 2004.
• Baltimore Facility Sale: Track progress on the potential sale of the Baltimore physical facility as a liquidity improvement measure.
• Customer Concentration: Review the impact of the deferred contract mentioned in the MD&A on future revenue recognition.